Journal article icon

Journal article

Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly

Abstract:

Increasingly, clinical trials for Alzheimer’s disease (AD) are being conducted earlier in the disease phase and with biomarker confirmation using in vivo amyloid PET imaging or CSF tau and Aβ measures to quantify pathology. However, making such a pre-clinical AD diagnosis is relatively costly and the screening failure rate is likely to be high. Having a blood-based marker that would reduce such costs and accelerate clinical trials through identifying potential participants with likely pre-cli...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.3233/JAD-151155

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Psychiatry
Lovestone, S More by this author
Publisher:
IOS Press Publisher's website
Journal:
Journal of Alzheimer's Disease Journal website
Volume:
52
Issue:
2
Pages:
561-572
Publication date:
2016
Acceptance date:
2016-02-02
DOI:
EISSN:
1875-8908
ISSN:
1387-2877
URN:
uuid:2f813af8-53e7-493c-b84f-f013ad4586a0
Source identifiers:
613123
Local pid:
pubs:613123

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP